Lactobacillus casei PXN 37

What does the research say about Lactobacillus casei PXN 37?

2 health outcomes synthesised

Research on Lactobacillus casei PXN 37 has been conducted for two health outcomes: quality of life and inflammation. The strongest evidence, though still rated low in strength, comes from two meta-analyses totaling 703 participants that reported statistically significant reductions in inflammatory markers such as IL-6, TNFα, and hs-CRP. Studies have primarily involved patients with autoimmune diseases, neurodegenerative conditions, and colorectal cancer, but no consistent effective dose has been reported across the literature.

Strongest evidence

No outcomes currently meet high or moderate evidence strength ratings. Both studied outcomes—improved quality of life and reduced inflammation—are supported by low-strength evidence. However, the reduction of inflammation shows the most robust quantitative support: 2 of 3 studies were meta-analyses (total n=703) that found statistically significant decreases in IL-6, TNFα, and hs-CRP, with moderate effect sizes.

Mixed or weaker evidence

For quality of life, all 3 systematic reviews reported beneficial effects, but none found statistically significant improvements. The evidence base is small (3 papers) and subject to publication bias. Doses, forms, and durations were inconsistently reported, limiting the reliability of the findings.

Effective dose patterns

No consistent effective dose emerged across studies. The syntheses did not specify doses or forms used, making cross-outcome dose comparisons impossible.

Population insights

Study populations overlap across both outcomes: patients with neurodegenerative diseases (Alzheimer’s, Parkinson’s, multiple sclerosis, mild cognitive impairment), autoimmune conditions, and gastrointestinal diseases. The inflammation outcome additionally included depressed patients with somatic comorbidities, while quality-of-life studies included colorectal cancer patients undergoing chemotherapy.

Notable caveats

The evidence base is small (only 3 studies per outcome) and considered preliminary.
Publication bias is a concern—null results are less likely to be published or indexed.
For quality of life, no individual study reported statistically significant effects, despite a uniformly beneficial direction.
Doses, forms, and treatment durations were not consistently described, preventing dose-response conclusions.

Frequently asked

What is Lactobacillus casei PXN 37 good for according to research?
Research has investigated Lactobacillus casei PXN 37 for two outcomes: reducing inflammation and improving quality of life. Both areas show a predominantly beneficial direction across all 3 studies each, but the evidence strength is rated low. The inflammation outcome has stronger quantitative support, with two meta-analyses showing significant reductions in inflammatory markers.
What dose of Lactobacillus casei PXN 37 is typically used in studies?
No consistent dose, form, or duration has been reported across the included studies. The syntheses did not specify effective doses, so there is insufficient data to determine a typical or optimal dose from the current evidence.
Who benefits most from Lactobacillus casei PXN 37?
The studied populations include patients with autoimmune diseases, neurodegenerative diseases (Alzheimer's, Parkinson's, multiple sclerosis, mild cognitive impairment), gastrointestinal diseases, and colorectal cancer undergoing chemotherapy. For inflammation, benefits were also observed in depressed patients with somatic comorbidities. The evidence does not yet allow comparisons of benefit magnitude across these groups.
Are there caveats or limitations in the research on Lactobacillus casei PXN 37?
Yes. The evidence base is small (only 3 studies per outcome) and rated low strength. Publication bias is a concern, as null findings may be underrepresented. For quality of life, none of the studies reported statistically significant results. Doses and forms were not consistently described, limiting the applicability of findings.
Does Lactobacillus casei PXN 37 help with inflammation?
All 3 studies reported beneficial effects, with two meta-analyses (total n=703) finding statistically significant reductions in inflammatory markers such as IL-6, TNFα, and hs-CRP. The effect size is moderate, but the overall evidence strength is low due to the small number of studies and potential publication bias.
Does Lactobacillus casei PXN 37 improve quality of life?
All 3 systematic reviews reported a beneficial direction for quality of life, with predominantly moderate effect sizes. However, none of the included studies found statistically significant improvements, and the evidence base is small and preliminary. No consistent dose or population-specific effects have been identified.

Most-studied combinations with Lactobacillus casei PXN 37

most supplement research is combination research

Also studied with:Lactobacillus rhamnosus PXN 54 (6), Streptococcus thermophilus PXN 66 (8)